Anti-CD20 x Anti-CD28 Bispecific Antibody (IgG-IgG) (BSIG-H225)

Anti-CD20 x Anti-CD28 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD20 and anti-CD28 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Lymphoma therapy.

Datasheet

Specifications

Targets

CD20 & CD28

Type

IgG-IgG

Species Reactivity

Human

Target 1

CD20

Host Animal 1

Human

Target 2

CD28

Host Animal 2

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Lymphoma

Targets

Target 1

CD20

Gene ID

931

UniProt ID

A0A024R507

Alternative Names

MS4A1; membrane-spanning 4-domains, subfamily A, member 1; B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; B-lymphocyte antigen CD20; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1

Target 2

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

45-1 Ramsey Road, Shirley, NY 11967, USA
Email:
Fax: 1-631-207-8356
Or Call
Tel: 1-631-381-2994